MARKERS TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY

• US 20100196907A1
• Filed: 01/29/2010
• Published: 08/05/2010
• Est. Priority Date: 01/31/2009
• Status: Abandoned Application

• Current Assignee: Abbvie Incorporated
• Original Assignee: Abbott Laboratories
• Inventors: Guo, Jun, Anderson, Mark G., Shah, Jameel, Semizarov, Dimitri
• Application Number:
  US12/696,116
• Publication Number:
  US 20100196907A1
• Time in Patent Office: Days
• US Class Current: 435/6.18
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates to identifying the presence or absence of one or more copy number gains in the ABCB1 gene, the ABCB4 gene or combinations thereof, identifying patients eligible to receive Aurora kinase inhibitor therapy, either as monotherapy or as part of combination therapy, and monitoring patients'"'"' response to such therapy.

Claims

1. A method of classifying a patient for eligibility for treatment with an Aurora kinase B inhibitor, the method comprising the steps of:

a) receiving a test sample from a patient;

b) determining the presence or absence of a copy number gain for the (1) ABCB1 gene at chromosome locus 7q21.1;

or (2) ABCB4 gene at chromosome locus 7q21.1, wherein the determining is performed by in situ hybridization, polymerase chain reaction, or nucleic acid microarray assay; and

c) classifying the patient as being eligible for receiving treatment with an Aurora kinase B inhibitor based on the presence or absence of a copy number gain for the (1) ABCB1 gene at chromosome locus 7q21.1;

or (2) ABCB4 gene at chromosome locus 7q21.1.

2. The method of claim 1, wherein the Aurora kinase B inhibitor is AZD1152, ZM447439, VX-680/MK0457 or Hersperadin.

3. The method of claim 1, wherein the test sample comprises a tissue sample.

4. The method of claim 3, wherein the tissue sample comprises a peripheral blood sample, a tumor tissue or a suspected tumor tissue, a thin layer cytological sample, a fine needle aspirate sample, a bone marrow sample, a lymph node sample, a urine sample, an ascites sample, a lavage sample, an esophageal brushing sample, a bladder or lung wash sample, a spinal fluid sample, a brain fluid sample, a ductal aspirate sample, a nipple discharge sample, a pleural effusion sample, a fresh frozen tissue sample, a paraffin embedded tissue sample or an extract or processed sample produced from any of a peripheral blood sample, a tumor tissue or a suspected tumor tissue, a thin layer cytological sample, a fine needle aspirate sample, a bone marrow sample, a urine sample, an ascites sample, a lavage sample, an esophageal brushing sample, a bladder or lung wash sample, a spinal fluid sample, a brain fluid sample, a ductal aspirate sample, a nipple discharge sample, a pleural effusion sample, a fresh frozen tissue sample or a paraffin embedded tissue sample.

5. The method of claim 1, wherein the in situ hybridization is performed with a nucleic acid probe that is fluorescently labeled.

6. The method of claim 1, wherein the in situ hybridization is performed with at least two nucleic acid probes.

7. The method of claim 1, wherein the in situ hybridization is performed with a peptide nucleic acid probe.

8. The method of claim 1, wherein the cancer is colorectal carcinoma or pancreatic carcinoma.

9. The method of claim 1, wherein the presence of a copy number gain in the ABCB1 gene correlates with an increase in expression of the MDR1 polypeptide.

10. The method of claim 1, wherein the presence of a copy number gain in the ABCB4 gene correlates with an increase in expression of the MDR3 polypeptide.

11. A method of classifying a patient having a cancer that is resistant to treatment with an Aurora kinase B inhibitor, the method comprising the steps of:

a) receiving a test sample from a patient;

b) determining the presence or absence of a copy number gain for the (1) ABCB1 gene at chromosome locus 7q21.1;

or (2) ABCB4 gene at chromosome locus 7q21.1, wherein the determining is performed by in situ hybridization, polymerase chain reaction, or nucleic acid microarray assay;

c) comparing the presence or absence of the copy number gain for the ABCB1 gene or the ABCB4 gene in the test sample against a baseline level or a predetermined level; and

d) classifying the patient as having a cancer that is resistant to Aurora kinase B inhibitor treatment on (i) the presence of a copy number gain in the ABCB1 gene or the ABCB4 gene at chromosome locus 7q21.1; and

(ii) if the copy number gain in the test sample is higher then the baseline level or the predetermined level.

12. The method of claim 11, wherein the Aurora kinase inhibitor is AZD1152, ZM447439, VX-680/MK0457 or Hersperadin.

13. The method of claim 11, wherein the test sample comprises a tissue sample.

14. The method of claim 13, wherein the tissue sample comprises a peripheral blood sample, a tumor tissue or a suspected tumor tissue, a thin layer cytological sample, a fine needle aspirate sample, a bone marrow sample, a lymph node sample, a urine sample, an ascites sample, a lavage sample, an esophageal brushing sample, a bladder or lung wash sample, a spinal fluid sample, a brain fluid sample, a ductal aspirate sample, a nipple discharge sample, a pleural effusion sample, a fresh frozen tissue sample, a paraffin embedded tissue sample or an extract or processed sample produced from any of a peripheral blood sample, a tumor tissue or a suspected tumor tissue, a thin layer cytological sample, a fine needle aspirate sample, a bone marrow sample, a urine sample, an ascites sample, a lavage sample, an esophageal brushing sample, a bladder or lung wash sample, a spinal fluid sample, a brain fluid sample, a ductal aspirate sample, a nipple discharge sample, a pleural effusion sample, a fresh frozen tissue sample or a paraffin embedded tissue sample.

15. The method of claim 11, wherein the in situ hybridization is performed with a nucleic acid probe that is fluorescently labeled.

16. The method of claim 11, wherein the in situ hybridization is performed with at least two nucleic acid probes.

17. The method of claim 11, wherein the in situ hybridization is performed with a peptide nucleic acid probe.

18. The method of claim 11, wherein the cancer is colorectal carcinoma or pancreatic carcinoma.

19. The method of claim 11, wherein the presence of a copy number gain in the ABCB1 gene correlates with an increase in expression of the MDR1 polypeptide.

20. The method of claim 11, wherein the presence of a copy number gain in the ABCB4 gene correlates with an increase in expression of the MDR3 polypeptide.

21. A kit comprising:

(a) reagents for determining the presence or absence of a copy number gain for the ABCB1 gene;

(b) instructions for performing the test.

22. The kit of claim 21, wherein the reagents to determine the presence or absence of a copy number gain comprise detectably-labeled polynucleotides that hybridize to at least a portion of the ABCB1 gene.

23. A kit comprising:

(a) reagents for determining the presence or absence of a copy number gain for the ABCB4 gene;

(b) instructions for performing the test.

24. The kit of claim 23, wherein the reagents to determine the presence or absence of a copy number gain comprise detectably-labeled polynucleotides that hybridize to at least a portion of the ABCB4 gene.